Form 4: Amphastar CFO Reports Future Stock Sale for Tax

Amphastar Pharmaceuticals' CFO, William J. Peters, reported a planned disposal of 1,973 shares of common stock on March 15, 2026, to cover tax liabilities from restricted stock unit vesting.

Summary

• William J. Peters, who serves as Director, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, Inc. (AMPH), reported a transaction.
• The transaction involves the disposal of 1,973 shares of Amphastar Common Stock.
• The disposal is scheduled for March 15, 2026, at a price of $18.18 per share.
• The shares are being withheld to satisfy tax liabilities associated with the vesting of restricted stock units (RSUs).
• Following this transaction, William J. Peters will beneficially own 175,063 shares of Common Stock.
• The transaction is indicated as being made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine administrative transaction related to executive compensation and tax obligations, not indicative of a positive or negative strategic shift or financial performance.

Future Outlook

The filing does not provide a future outlook for the company's performance or strategic direction; it solely reports a planned insider transaction related to compensation.

Management Comments

• "The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs."

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax withholdings from RSU vesting, are common occurrences across all industries for executives receiving equity compensation. This specific filing for Amphastar Pharmaceuticals reflects a routine administrative event rather than a strategic move or a direct reflection of the company's immediate operational performance.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary sale for tax purposes and represents a small fraction of the company's outstanding shares and the insider's total holdings.
• Employees: No direct impact on general employees.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, RSU Vesting, William J. Peters, CFO